Skip to main content

Bureau Veritas: acquisition of Galbraith Laboratories Inc., a US expert in Healthcare analytical testing solutions

Written by Customer Service on . Posted in Mergers And Acquisitions.

PRESS RELEASE

Neuilly-sur-Seine, France – September 19, 2022

Bureau Veritas acquires Galbraith Laboratories Inc.,
a US expert in Healthcare analytical testing solutions

Expanding BV’s position in Consumer Healthcare, Personal Care & Industrial Chemical markets

Bureau Veritas, a world leader in testing, inspection and certification, announced the acquisition of Galbraith Laboratories Inc., an expert in advanced analytical solutions in North America.

The acquisition will further position Bureau Veritas in the Consumer Healthcare and Industrial Chemical supply chain by connecting our existing services to support upstream research and product development through manufacturing to the end consumer.

Galbraith Laboratories Inc. offers testing solutions to a wide range of industry segments, including chemicals, healthcare, cosmetics, consumer, manufacturing and environment. The company has earned a strong reputation for solving clients’ analytical challenges through custom-developed methods and industry-specific knowledge.
Founded in 1950 and headquartered in Knoxville (Tennessee, USA), the company employs approximately 70 people and generated revenue of €8 million in 2021.

Didier Michaud-Daniel, Chief Executive Officer of Bureau Veritas, commented: 

“Bureau Veritas is delighted to welcome the Galbraith team. By joining forces, we will strengthen our presence in North America, a key hub for the expansion of our Consumer Products Services activities. Building on its strong market recognition by global brands and manufacturers, Galbraith’s expertise will help expand our analytical capabilities in the Consumer Healthcare, Personal Care & Industrial Chemical markets.”

Brenda Thornburgh, Owner of Galbraith, added: 

“By joining Bureau Veritas, we look forward to expanding our capabilities and client services by leveraging the Group’s extensive geographic footprint and global leadership. We are proud of our advanced analytical capabilities, which we now share with Bureau Veritas worldwide. Through our combined expertise, we will be able to offer unique analytical testing services solutions to our clients.”

About Bureau Veritas
Bureau Veritas is a world leader in laboratory testing, inspection and certification services. Created in 1828, the Group has more than 80,000 employees located in nearly 1,600 offices and laboratories around the globe. Bureau Veritas helps its 400,000 clients improve their performance by offering services and innovative solutions in order to ensure that their assets, products, infrastructure and processes meet standards and regulations in terms of quality, health and safety, environmental protection and social responsibility.
Bureau Veritas is listed on Euronext Paris and belongs to the CAC 40 ESG, CAC Next 20 and SBF 120 indices.
Compartment A, ISIN code FR 0006174348, stock symbol: BVI.
For more information, visit www.bureauveritas.com, and follow us on Twitter (@bureauveritas) and LinkedIn.

 Our information is certified with blockchain technology.
Check that this press release is genuine at www.wiztrust.com.

ANALYST/INVESTOR CONTACTS MEDIA CONTACTS  

Laurent Brunelle Caroline Ponsi Khider
+33 (0)1 55 24 76 09 +33 (0)7 52 60 89 78
laurent.brunelle@bureauveritas.com caroline.ponsi-khider@bureauveritas.com
   
Colin Verbrugghe Primatice
+33 (0)1 55 24 77 80 thomasdeclimens@primatice.com
colin.verbrugghe@bureauveritas.com

 

 armandrigaudy@primatice.com

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.